BioCentury
ARTICLE | Clinical News

Pharmos starts Phase III brain injury study

January 10, 2001 8:00 AM UTC

PARS began the European portion of its Phase III study of dexanabinol synthetic non-psychotropic cannabinoid analog to treat severe traumatic brain injury. The U.S. arm of the trial is expected to beg...